VivoSeq
Oncology

Early Breast Cancer

11

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Early Breast Cancer is an emerging landscape with 11 programs across 7 companies. The most active players are Novartis, AstraZeneca, Roche. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

38/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

3 programs

Phase 3AstraZeneca logo

AstraZeneca

2 programs

Phase 3Roche logo

Roche

1 program

Phase 3T

TerSera Therapeutics LLC

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 311

Giredestrant

Roche

Ribociclib

Novartis

Letrozole

Novartis

Ansastrozole

Novartis

Goserelin

TerSera Therapeutics LLC

Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Completed1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Recruiting·Novartis logoNovartis·Phase 3·NCT05827081·1,400 enrolled
Pragmatic Randomized Trial to Evaluate the Impact of Various Interventions to Increase the Uptake of Surveillance Mammography in Eligible Women in Singapore
Completed·NNational University Hospital, Singapore·Preclinical·NCT06733155·12,000 enrolled
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT05952557·5,500 enrolled
A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy
Not yet recruiting·Roche logoRoche·Phase 3·NCT07541079·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)